Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis
Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
ObjectivesWe aimed to assess the expression of the CCL24 chemokine in systemic sclerosis (SSc) and to evaluate the possible pathogenic implications of the CCL24/CCR3 axis using both in vitro and in vivo models. We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal an...
Alternative Titles
Full title
Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6788878
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6788878
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2019-215119
